IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

An Overview Of Cancer Pharmacology: Principles, Challenges, And Future Directions

AUTHOR: SHRUTI DAHIYA

ABSTRACT

Cancer pharmacology is a dynamic and rapidly advancing field focused on understanding the molecular and cellular mechanisms of anticancer agents, their pharmacokinetics, pharmacodynamics, and resistance patterns. With cancer being a global health burden, the evolution of pharmacological therapies from traditional cytotoxic drugs to targeted and immune-based therapies has transformed the treatment landscape. This review article explores the fundamentals of cancer pharmacology, categorization of anticancer drugs, drug resistance, side effects, and the emergence of personalized medicine, concluding with current challenges and future prospects.

1. INTRODUCTION

Cancer remains a major cause of morbidity and mortality worldwide. According to the World Health Organization (2024), cancer accounts for approximately 10 million deaths annually. Treatment modalities have diversified significantly over the past decades, with pharmacological intervention becoming central to both curative and palliative care. Cancer pharmacology bridges the disciplines of oncology, pharmacokinetics, toxicology, and molecular biology to develop and optimize treatments that improve survival and quality of life.

2. PHARMACOLOGICAL BASIS OF CANCER THERAPY

The core principle of cancer pharmacology is selective toxicity—targeting rapidly dividing tumor cells while sparing normal cells. However, many anticancer drugs also affect healthy proliferative tissues, leading to dose-limiting side effects.

Key pharmacologic factors:

- **Pharmacodynamics:** Mechanism of drug action at the molecular level.
- **Pharmacokinetics (ADME):** Absorption, Distribution, Metabolism, and excretion of drugs.

Understanding the drug–tumor interaction enables better therapeutic outcomes.

3. CLASSIFICATION OF ANTICANCER AGENTS

3.1 Cytotoxic Chemotherapy

- **Alkylating Agents** (e.g., Cyclophosphamide): Induce DNA cross-linking, impairing replication.
- **Antimetabolites** (e.g., 5-Fluorouracil, Methotrexate): Mimic nucleotide precursors, inhibiting DNA/RNA synthesis.

- **Topoisomerase Inhibitors** (e.g., Doxorubicin): Disrupt DNA coiling during cell division.
- **Microtubule Inhibitors** (e.g., Paclitaxel): Block mitosis by destabilizing microtubules.

3.2 Targeted Therapies• **Tyrosine Kinase Inhibitors (TKIs)** (e.g., Imatinib): Block mutated or overexpressed kinase pathways.

- **Monoclonal Antibodies** (e.g., Trastuzumab): Bind to surface proteins like HER2, inhibiting growth.

3.3 Hormonal Therapies

- Used in hormone-sensitive cancers such as breast and prostate cancer.
- Examples: Tamoxifen (anti-estrogen), Leuprolide (GnRH agonist)

3.4 Immunotherapy

- **Checkpoint Inhibitors** (e.g., Nivolumab, Pembrolizumab): Reactivate suppressed T-cells.
- **CAR-T Cell Therapy:** Genetically engineered T-cells designed to target tumor antigens.

3.5 Anti-Angiogenic Agents

- **Bevacizumab:** Inhibits VEGF, disrupting tumor blood supply.

4. MECHANISMS OF DRUG RESISTANCE

Resistance is a major hurdle in cancer pharmacology. It can be:

- Primary (Intrinsic): Tumors do not respond from the beginning.
- Acquired: Resistance develops after initial responsiveness.

Mechanisms include:

- Efflux Pumps (e.g., P-glycoprotein): Reduce intracellular drug concentration.
- Mutation in Drug Targets: Prevent effective binding.
- Enhanced DNA Repair: Counteracts DNA-damaging drugs.
- Apoptosis Evasion: Mutations in pro-apoptotic proteins.

5. TOXICITY AND ADVERSE EFFECTS

Most anticancer agents also affect normal rapidly dividing cells. Common side effects:
- Myelosuppression (↓ WBC, platelets, RBCs)
- Gastrointestinal toxicity (nausea, mucositis)
- Alopecia
- Peripheral neuropathy
- Cardiotoxicity (e.g., Doxorubicin)

Supportive care involves:
- Anti-emetics
- Colony-stimulating factors
- Pain management
- Nutritional support

6. PERSONALIZED AND PRECISION MEDICINE

Personalized medicine is a growing branch in cancer pharmacology, driven by genomics and molecular diagnostics.

Applications:

- EGFR mutations: guide TKI use in lung cancer.
- BRCA mutations: indicate benefit from PARP inhibitors.
- Pharmacogenomics: Predicts drug metabolism (e.g., CYP450 enzymes) to minimize toxicity.

7. EMERGING APPROACHES

a. Nanomedicine

- Liposomes and nanoparticles improve targeted delivery, reducing systemic toxicity.

b. Epigenetic Therapy

- Drugs like Azacitidine and Vorinostat reverse gene silencing in cancer cells.

c. Artificial Intelligence (AI)

- AI assists in drug design, predicting toxicity and identifying novel compounds.

d. Cancer Vaccines

- Sipuleucel-T (prostate cancer): Activates immune system against cancer antigens.

8. CHALLENGES IN CANCER PHARMACOLOGY

- High costs of novel therapies
- Resistance development
- Access issues in low- and middle-income countries
- Ethical concerns in experimental therapies
- Long drug development timelines

9. CONCLUSION

Cancer pharmacology is evolving rapidly, bridging biology and therapeutics to improve patient outcomes. Traditional chemotherapies are being complemented and replaced by targeted, immune, and gene-based therapies. The future lies in integrating precision medicine, AI, and global access to create equitable and effective cancer care for all.

10. REFERENCES

1. World Health Organization. (2024). Cancer Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/cancer
2. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646–
3. 674.
4. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653.
5. Druker BJ, et al. Imatinib in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–
6. 1037.
7. 5. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–
8. 61.
9. 6. Holohan C, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer.
10. 2013;13(10):714–726.
11. 7. Vamathevan J, et al. Machine learning in drug discovery. Nat Rev Drug Discov.
12. 2019;18(6):463–477.